[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zai Lab Ltd ADR (ZLAB)

Zai Lab Ltd ADR (ZLAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,027,824
  • Shares Outstanding, K 113,413
  • Annual Sales, $ 460,160 K
  • Annual Income, $ -175,540 K
  • EBIT $ -243 M
  • EBITDA $ -233 M
  • 60-Month Beta 0.78
  • Price/Sales 4.37
  • Price/Cash Flow N/A
  • Price/Book 3.04

Options Overview Details

View History
  • Implied Volatility 80.54% (+16.14%)
  • Historical Volatility 51.72%
  • IV Percentile 61%
  • IV Rank 24.60%
  • IV High 181.89% on 02/04/26
  • IV Low 47.48% on 04/15/26
  • Expected Move (DTE 29) 2.69 (14.82%)
  • Put/Call Vol Ratio 1.33
  • Today's Volume 107
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 3.64
  • Today's Open Interest 5,868
  • Open Int (30-Day) 5,663
  • Expected Range 15.49 to 20.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) +270,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.26 +11.81%
on 06/09/26
19.18 -5.21%
on 05/21/26
-0.68 (-3.61%)
since 05/18/26
3-Month
16.26 +11.81%
on 06/09/26
25.28 -28.09%
on 04/20/26
-0.65 (-3.45%)
since 03/18/26
52-Week
15.96 +13.91%
on 02/02/26
41.20 -55.87%
on 07/29/25
-18.75 (-50.77%)
since 06/18/25

Most Recent Stories

More News
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

- European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized...

ZLAB : 18.18 (+1.68%)
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China - TIVDAK demonstrated...

ZLAB : 18.18 (+1.68%)
Zai Lab Announces Changes to Senior Leadership Team

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made...

ZLAB : 18.18 (+1.68%)
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary...

ZLAB : 18.18 (+1.68%)
Zai Lab Q1 Earnings Call Highlights

Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and...

ZLAB : 18.18 (+1.68%)
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related...

ZLAB : 18.18 (+1.68%)
Zai Lab: Can China Commercial Momentum Offset the Guidance Vacuum Management Created?

Barchart Research What to Expect from ZLAB Earnings ZLAB Generated May 6, 2026 Current Price $21.01 EPS Estimate $$-0.58 Consensus Rating Moderate Buy Average Move 6.22% Zai Lab: Can China Commercial Momentum...

ZLAB : 18.18 (+1.68%)
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)

ZLAB : 18.18 (+1.68%)
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases ...

ZLAB : 18.18 (+1.68%)
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

  Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases;...

ZLAB : 18.18 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China....

See More

Key Turning Points

3rd Resistance Point 19.77
2nd Resistance Point 19.44
1st Resistance Point 18.81
Last Price 18.18
1st Support Level 17.85
2nd Support Level 17.52
3rd Support Level 16.89

See More

52-Week High 41.20
Fibonacci 61.8% 31.56
Fibonacci 50% 28.58
Fibonacci 38.2% 25.60
Last Price 18.18
52-Week Low 15.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.